Exploratory Biomarker Analysis of Neoadjuvant Chemoimmunotherapy Followed by Pulmonary Resection in Stage II-III Non-Small Cell Lung Cancer

Recruiting now

Conditions studied: Clinical Stage II to III Non-Small Cell Lung Cancer

In brief

1. To explore tissue-based biomarkers to select patients who do not respond to neoadjuvant immunotherapy (non-responders) at the point of diagnosis 2. To explore blood-based non-invasive biomarkers to predict pathological complete response (pCR) before surgery

Key facts

Study ID

NCT06907160

Run by

Yonsei University

People needed

100

Starts

2024-08-07

Expected to finish

2029-06-30

Last updated by the study team

2025-04-02

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically proven clinical stage II-III lung cancer patients
• No driver mutations (EGFR mutation and ALK alteration)
• Whole body performance (ECOG) 0-1
• Those over 19 years of age
• Subject who submitted Informed consent form

You may not qualify if…

• Under 19 years of age
• If there is a history of causing infection or other serious medical problems that impair the patient's function and make it difficult to comply with the study protocol.
• Patients for whom the investigator determines that the patient should not participate in the clinical trial because the patient is judged to be unable to comply with the clinical trial procedures and requirements (a person lacking medical capacity)
• Other patients (pregnant women, etc.) determined by the clinical trial director to be unsuitable for this clinical trial.

Where it is running

• Department of Thoracic and Cardiovascular Surgery, Severance Hospital, Yonsei University College of Medicine — Seoul, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.